The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b

被引：107
|
作者：
Rice, GPA
Paszner, B
Oger, J
Lesaux, J
Paty, D
Ebers, G
机构：
[1] London MS Clin, London, ON N6A 5A5, Canada
[2] Univ British Columbia, MS Clin, Vancouver, BC V5Z 1M9, Canada
来源：
NEUROLOGY | 1999年 / 52卷 / 06期
关键词：
D O I：
10.1212/WNL.52.6.1277
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The fate of the neutralizing antibody (NAB) in MS patients treated with interferons remains unclear. We conducted a follow-up survey of NAB titers in 59 long-term treated patients from the London and Vancouver cohorts of the pivotal trial of interferon beta-1b. NAB were measured with the myxovirus protein A assay and an ELISA, at a mean follow-up that exceeded 8 years. NAB disappeared in the majority of patients.
引用
收藏
页码：1277 / 1279
页数：3
相关论文
共 50 条
  • [41] Comparison of interferon β-1a subcutaneous and interferon β-1b on medication adherence in patients with multiple sclerosis
    Joyeux, A.
    Meletiche, D.
    Kozma, C.
    Dickson, M.
    Bennett, R.
    JOURNAL OF NEUROLOGY, 2009, 256 : S162 - S163
  • [42] Deficient Phosphorylation of Stat1 in Leukocytes Identifies Neutralizing Antibodies in Multiple Sclerosis Patients Treated with Interferon-Beta
    Gavasso, Sonia
    Mosleth, Ellen Faergestad
    Maroy, Tove
    Jorgensen, Katarina
    Nakkestad, Hanne-Linda
    Gjertsen, Bjorn-Tore
    Myhr, Kjell-Morten
    Vedeler, Christian
    PLOS ONE, 2014, 9 (02):
  • [43] Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b
    Giovannoni, G
    NEUROLOGY, 2003, 61 (07) : 1025 - 1025
  • [44] Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b
    Polman, C
    Kappos, L
    White, R
    Dahlke, F
    Beckmann, K
    Pozzilli, C
    Thompson, A
    Petkau, J
    Miller, D
    NEUROLOGY, 2003, 60 (01) : 37 - 43
  • [45] Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies
    Scagnolari, Carolina
    Duda, Petra
    Bagnato, Francesca
    De Vito, Gabriella
    Alberelli, Alessia
    Lavolpe, Vito
    Girardi, Enrico
    Durastanti, Valentina
    Trojano, Maria
    Kappos, Ludwig
    Antonelli, Guido
    JOURNAL OF NEUROLOGY, 2007, 254 (05) : 597 - 604
  • [46] Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies
    Carolina Scagnolari
    Petra Duda
    Francesca Bagnato
    Gabriella De Vito
    Alessia Alberelli
    Vito Lavolpe
    Enrico Girardi
    Valentina Durastanti
    Maria Trojano
    Ludwig Kappos
    Guido Antonelli
    Journal of Neurology, 2007, 254 : 597 - 604
  • [47] Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis
    Hyun, Jae-Won
    Kim, Gayoung
    Kim, Yeseul
    Kong, Byungsoo
    Joung, Aeran
    Park, Na Young
    Jang, Hyunmin
    Shin, Hyun-June
    Kim, Su-Hyun
    Ahn, Suk-Won
    Shin, Ha Young
    Huh, So-Young
    Kim, Woojun
    Park, Min Su
    Kim, Byung-Jo
    Kim, Byoung Joon
    Oh, Jeeyoung
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2018, 14 (02): : 186 - 190
  • [48] Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis
    Petkau, J
    White, R
    MULTIPLE SCLEROSIS, 1997, 3 (06): : 402 - 402
  • [49] Interferon β-1b retinopathy during a treatment for multiple sclerosis
    Sommer, S
    Sablon, JC
    Zaoui, M
    Rozot, P
    Hosni, A
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2001, 24 (05): : 509 - 512
  • [50] Therapy with Interferon β-1b of a Patient with Childhood Multiple Sclerosis
    Huppke, P.
    Gaertner, J.
    AKTUELLE NEUROLOGIE, 2009, 36 : S271 - S273
12345